CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | MicrobiomeTrials← Back to trialsNCT04668885
CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-01-14Est. Completion: 2026-01-19
Enrollment target: 13 participants Locations- Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Other microbiome trials you might be interested in
Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children…
Minneapolis, United StatesEst. completion Mar 31, 2027
Myelodysplastic Syndromes
Background:
Myelodysplastic syndrome (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are blood disorder…
Bethesda, United States
Est. completion Jan 1, 2030